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Exosomes are nanoscale extracellular vesicles that play an important
role in many biological processes, including intercellular communi-
cations, antigen presentation, and the transport of proteins, RNA,
and other molecules. Recently there has been significant interest in
exosome-related fundamental research, seeking new exosome-
based biomarkers for health monitoring and disease diagnoses.
Here, we report a separation method based on acoustofluidics
(i.e., the integration of acoustics and microfluidics) to isolate
exosomes directly from whole blood in a label-free and contact-
free manner. This acoustofluidic platform consists of two modules: a
microscale cell-removal module that first removes larger blood
components, followed by extracellular vesicle subgroup separation
in the exosome-isolation module. In the cell-removal module, we
demonstrate the isolation of 110-nm particles from a mixture of
micro- and nanosized particles with a yield greater than 99%. In the
exosome-isolation module, we isolate exosomes from an extracel-
lular vesicle mixture with a purity of 98.4%. Integrating the two
acoustofluidic modules onto a single chip, we isolated exosomes
from whole blood with a blood cell removal rate of over 99.999%.
With its ability to perform rapid, biocompatible, label-free, contact-
free, and continuous-flow exosome isolation, the integrated acous-
tofluidic device offers a unique approach to investigate the role
of exosomes in the onset and progression of human diseases with
potential applications in health monitoring, medical diagnosis,
targeted drug delivery, and personalized medicine.
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Exosomes are cell-derived nanovesicles (1), ≈30‒150 nm indiameter, that carry nucleic acids, proteins, lipids, and other
molecules from their cells of origin (2, 3). Exosomes transfer
RNA and proteins to the cells they fuse with and play important
roles in cell-to-cell communication. Recent research into the
characteristics and mechanisms involving exosomes has in-
troduced the potential development of biomarkers for health
monitoring and diagnosis of a number of human diseases, in-
cluding cancer (4), neurodegenerative disease (5), and diseases
of the kidney (6), liver (7), and placenta (8). Exosomes represent
a unique research opportunity because they are found in nearly
all biological fluids (9–11), including blood, saliva, urine, semen,
sputum, breast milk, and cerebrospinal fluid. Unlike tissue
samples, they can be collected noninvasively over a long period,
allowing for continuous monitoring of disease progression and
response to therapy. Exosomes also have several advantages over
other circulating biomarkers. They are abundant (thousands to
billions per microliter of biofluid), and their durability suggests
that their internal integrity can be preserved through several
freeze-and-thaw cycles.
Currently, differential centrifugation (including gradient ul-
tracentrifugation), which relies on multiple centrifugation steps
to sequentially remove whole cells, cellular debris, and subgroups
of extracellular vesicles (EVs) based on their different sizes and
densities, is a standard technology for isolating exosomes (12,
13). While differential centrifugation achieves high purity, it is
time-consuming (several hours to days), expensive, and in-
efficient (in that the exosome isolation yields from whole blood
are typically low, 5‒40% of preseparation exosome population)
(12, 14–17). It also requires trained personnel to operate.
Moreover, the high centrifugal force used in ultracentrifugation
(100,000‒200,000 × g) has been shown to cause exosome fusion,
promote coagulation, and alter their structures, properties, and
functions, which may impact downstream analysis (12, 13, 18).
Other methods, including immunoaffinity capture (19, 20), pre-
cipitation kits such as ExoQuick (System Biosciences) and Total
Exosome Isolation (Invitrogen) (12, 21), microfluidics (17, 22,
23), nanoscale lateral displacement arrays (24), nanostructure-
based filtration (25), nanoplasmonic chip (26), magnetoelectro-
chemical sensor (27), and dialysis membrane filtration (28), have
been implemented. However, these methods frequently suffer
from drawbacks such as the need for additional reagents/labels,
long processing time, low reproducibility, low exosome integrity,
low exosome purity, and/or low exosome yield.
Acoustic waves are well-recognized for their high precision
and biocompatibility in manipulating cells and other bioparticles
Significance
We have developed a unique, integrated, on-chip technology that
is capable of isolating exosomes or other types of extracellular
vesicles, directly from undiluted whole-blood samples in an au-
tomated fashion. Automated exosome isolation enables bio-
hazard containment, short processing time, reproducible results
with little human intervention, and convenient integration with
downstream exosome analysis units. Our method of integrating
acoustics and microfluidics leads to the isolation of exosomes with
high purity and yield. With its label-free, contact-free, and bio-
compatible nature, it offers the potential to preserve the struc-
tures, characteristics, and functions of isolated exosomes. This
automated, point-of-care device can further help in advancing
exosome-related biomedical research with potential applications
in health monitoring, disease diagnostics, and therapeutics.
Author contributions: M.W., Y.O., S.S., Y.S., and T.J.H. designed research; M.W., Y.O., Z.W.,
R.Z., C.C., and H.L. performed research; M.W., Y.O., Y.S., and T.J.H. contributed new re-
agents/analytic tools; M.W., Y.O., P.-H.H., P.L., D.Q., M.D., S.S., Y.S., and T.J.H. analyzed data;
and M.W., Y.O., P.-H.H., P.L., D.Q., M.D., S.S., Y.S., and T.J.H. wrote the paper.
Reviewers: G.B., Rice University; and M.T.A.S., University of Illinois at Urbana–Champaign.
The authors declare no conflict of interest.
Freely available online through the PNAS open access option.
1To whom correspondence may be addressed. Email: mingdao@mit.edu, ssuresh@ntu.edu.sg,
ysadovsky@mwri.magee.edu, or tony.huang@duke.edu.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1709210114/-/DCSupplemental.
10584–10589 | PNAS | October 3, 2017 | vol. 114 | no. 40 www.pnas.org/cgi/doi/10.1073/pnas.1709210114
(29–34). Current acoustic-based separation strategies, however,
can only handle biological fluids (such as undiluted blood), which
must be preprocessed before exosome separation, and thus re-
quire additional equipment and time, and are subject to the risk
of sample loss. Additionally, current acoustic separation strate-
gies can only differentiate two types of targets, making it difficult
to isolate exosomes directly from complex multicomponent flu-
ids such as undiluted blood.
Here, we demonstrate an acoustofluidic platform (i.e., one that
involves the fusion of acoustics and microfluidics) which can iso-
late exosomes directly from undiluted blood samples. This
acoustofluidics-based, automated point-of-care system allows
single-step, on-chip isolation of exosomes from biological fluids
(such as blood, urine, saliva, plasma, and breast milk) or in vitro
cell cultures. It also represents a unique integration of two se-
quential surface acoustic wave (SAW) microfluidic modules,
comprising a cell-removal module and an exosome-isolation
module. Each module relies on a tilted-angle standing SAW
(taSSAW) field (29, 30) formed by one pair of interdigital trans-
ducers (IDTs). The cell-removal module first extracts microscale
blood components to obtain enriched EVs, while the exosome-
isolation module further purifies the exosomes by removing the
other EV subgroups. After optimizing the length, driving fre-
quency, and driving power of the IDTs in the two modules, we
successfully isolated exosomes from undiluted blood samples with
high purity and yield. Compared with existing methods, our acous-
tofluidic platform provides a simple, rapid, efficient, and poten-
tially cost-effective and biocompatible strategy.
Theory and Mechanism
Fig. 1 A and B presents a schematic view and a photograph of our
acoustofluidic platform, which includes a cell-removal module and
an exosome-isolation module arranged in series. The cell-removal
module is designed first to fractionate blood components larger
than 1 μm in diameter, including red blood cells (RBCs), white
blood cells (WBCs), and platelets (PLTs). This provides cell-free
plasma for downstream exosome isolation, which is optimized to
separate nanoscale bioparticles. By using a higher frequency (∼40
MHz) than those used in our previous acoustofluidic devices
designed for cell separation (30), the exosome-isolation module
is capable of discriminating submicrometer particles, such that
subgroups of EVs with larger size (including microvesicles and
apoptotic bodies), from exosomes. Fig. 1C illustrates the mecha-
nism for separating large particles from small ones due to the
deflection caused by acoustic pressure nodes tilted with respect to
the channel orientation. Particles are subjected to an acoustic
radiation force (Fr) generated by the SAW field, and are pushed
toward the pressure node. As particles move toward the pressure
nodes, their movement is impeded by the Stokes drag force (Fd).
The drag force is proportional to the radius of particles or cells
and the acoustic radiation force is proportional to the volume.
Thus, the acoustic radiation force dominates over the drag force
for larger particles, which causes the particle stream to migrate
toward the tilted nodes. Conversely, the drag force cancels a sig-
nificant part of acoustic radiation force out for smaller particles,
resulting in little lateral displacement. By adjusting the input
power, the cutoff particle diameter can be adjusted, giving our
device the flexibility to be used in a wide variety of applications.
More details can be found in SI Theory and Mechanism.
Results
Cell-Removal Module.To optimize parameters for the cell-removal
module, we first examined whether our method could separate
mixtures of synthetic particles of two different sizes using a
standalone cell-removal module. We first mixed polystyrene
particles of diameter 970 nm (representative of larger-diameter
EVs in human blood) and 5.84 μm (representative of blood cells
such as RBCs and WBCs). The 970-nm particles were conju-
gated with a green fluorophore, facilitating real-time tracking of
their trajectory during the course of separation. We forced the
particle mixture into a narrow, straight sample stream by in-
troducing two PBS sheath flows through two adjacent inlets.
Using an applied voltage of 22 Vpp (peak-to-peak voltage) and
driving frequency of 19.6 MHz, we were able to direct the 5.84-
μm-diameter particles toward the waste outlet, whereas the 970-
nm-diameter particles remained in the sample stream and exited
through the collection outlet (Fig. 2). We then repeated this
experiment, replacing the 970-nm particles with 110-nm poly-
styrene particles, which better represent exosomes. Using the
same cell-removal module, we could separate polystyrene par-
ticles of 110 nm from particles of 5 μm, with a recovery rate of
over 99% (Fig. S1). These results demonstrate the capability of
Fig. 1. Schematic illustration and mechanisms underlying integrated acous-
tofluidic device for isolating exosomes. (A) RBCs, WBCs, and PLTs are filtered by
the cell-removal module, and then subgroups of EVs (ABs: apoptotic bodies;
EXOs: exosomes; MVs: microvesicles) are separated by the exosome-isolation
module. (B) An optical image of the integrated acoustofluidic device. Two
modules are integrated on a single chip. (C) Size-based separation occurs in
each module due to the lateral deflection induced by a taSSAW) field. The
periodic distribution of pressure nodes and antinodes generates an acoustic
radiation force to push large particles toward node planes.
Fig. 2. Separation of synthetic microparticles and submicrometer particles
using the acoustofluidic cell-removal module. Polystyrene particles with di-
ameters of 5.84 μm (not labeled) and 970 nm (labeled with Dragon Green
fluorescent dye) were processed through the acoustic field. The taSSAW field
deflected microparticles to the waste outlets. The acoustic radiation force was
not sufficiently large to move the submicrometer particles, which were
therefore separated from microparticles at the outlet. White stripe in the two
left panels indicates the centerline location of the CCD (charge-coupled device)
image sensor. (Scale bar: 500 μm.)
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this acoustofluidic approach to isolate nanoparticles from a mix-
ture of nanoparticles and microparticles.
Based on the conditions optimized by our particle-separation
experiments, we proceeded to test our cell-removal module using
undiluted whole-blood samples, which contained the anticoagu-
lant EDTA. Because blood cells have a lower acoustic contrast
than polystyrene particles, we increased the applied voltage to 40
Vpp. To match the acoustic impedance of whole blood, a 5%
dextrose solution in PBS was used as sheath fluid. When the
taSSAW field was off, the whole-blood sample flowed into the
top outlet. Once the taSSAW was activated, blood components
such as RBCs, WBCs, and PLTs changed their flow route and
were delivered to the waste outlet (Fig. S2 A and B) and the
smaller EV-containing sample was collected.
Samples collected from the two outlets were measured using
nanoparticle tracking analysis (NTA) device and dynamic light
scattering (DLS). The sample collected at the waste outlet had a
visible peak at ∼5 μm, which contained primarily RBCs, while
the sample collected at the collection outlet, the isolated EVs
sample, contained no particles larger than 1 μm (Fig. 3 A and B),
thus suggesting that submicrometer particles, such as EVs, were
isolated. We used a scanning electron microscope (SEM) and
Western blotting to further characterize isolated EVs. The SEM
showed that the diameter of isolated EVs ranged between 50 and
300 nm (Fig. 3C). The Western immunoblotting showed that
samples from the waste outlet were positive for Integrin β1 (PLT
marker) and Glycophrin A (a representative marker of RBCs).
In contrast, our isolated EVs were immune-positive for CD63, a
tetraspanin characteristic of exosomal marker, and negative for
PLT and RBC markers (Fig. 3D). Collectively, these results
demonstrate that the acoustofluidic cell-removal module is ca-
pable of separating EVs directly from undiluted, anticoagulated
human blood samples.
Exosome-Isolation Module. To examine whether our exosome-
isolation module could separate EV subgroups, namely micro-
vesicles from exosomes, we input a mixture of purified exosomes
and microvesicles derived from primary human trophoblasts
(PHTs) to a standalone exosome-isolation module. The isolation
and culture of PHT cells from human placentas and the purification
of PHT-derived microvesicles and exosomes from PHT-conditioned
medium were described elsewhere (16). We identified an optimized
driving frequency of 39.4 MHz based on pilot experiments using a
nanoparticle mixture of 110 and 340 nm (Fig. S3). Then, we set the
sample flow rate and sheath flow rate as 4 and 8 μL/min, re-
spectively. With the standing SAW field switched on, and under an
input voltage of 45 Vpp, larger bioparticles were deflected and di-
rected to the waste outlet. We then conducted NTA of the isolated
samples from both outlets as well as of the original mixture of the
same volume. The original mixture of purified microvesicles and
exosomes exhibited a broad size distribution from ∼50 to 600 nm
(Fig. 4A); specifically, there was a single peak at 122 nm corre-
sponding to exosomes, whereas other peaks appeared between
170 and 300 nm, representing the broader distribution of micro-
vesicles rather than exosomes. Additionally, the concentration dis-
tribution curve reached a valley at 140 nm, which was therefore
chosen as the separation cutoff size. The sample at the collection
outlet exhibited two peaks, at ≈81 and 99 nm, which represented
slight shifts from the inlet peak corresponding to a size of 122 nm.
This difference may be attributed to the resolution limits of NTA
when testing highly heterogeneous samples. When we examined the
morphology of the isolated exosomes (Fig. 4C) using transmission
electron microscopy (TEM), the mean size of isolated vesicles was
∼100 nm, which is consistent with the NTA results and the pre-
dicted size of exosomes. In contrast, the sample collected from the
waste outlet exhibited several peaks larger than 170 nm, along with
very few components that were less than 100 nm. These results
demonstrated that our acoustofluidic device was able to separate
two distinct EVs from each other (i.e., PHT-derived microvesicles
from exosomes).
We further used NTA to quantify the concentrations of the
mixture of trophoblastic microvesicles and exosomes, isolated
microvesicles, and isolated exosomes. Given that the final
Fig. 3. Characterization of the cell-removal module. (A) Separation of EVs
from RBCs and other blood components. NTA was used to characterize the
isolated EVs from the collection outlet. (B) RBCs and other blood compo-
nents collected from waste outlet were characterized by DLS. The ordinate is
the relative intensity of signals measured. (C) SEM image of isolated EVs
sample loaded on a filter membrane. The EV sample contained vesicles of
diameters from ∼50 to 300 nm. (D) Western blot with expression of RBC
marker (GYPA), PLT marker (integrin β1), and EV markers (CD63). The pro-
teins from blood, cell waste sample, and isolated EVs were extracted and
prepared for electrophoresis.
Fig. 4. Separation of exosomes from microvesicles using the exosome-
isolation module. (A) Size distribution of original mixture (MIX), isolated
EXO, and MV samples. The data were obtained from at least three NTA
assays. The black line and the red area represent the fitting curve and the
error bar, respectively. The y axis is the concentration of particles. The peak
positions are marked. The green dashed line is located at 140 nm, which is
set as the cutoff size. (B) Quantitative characterization of exosome/micro-
vesicle separation, showing the concentrations of vesicle subgroups (cutoff
size at 140 nm) in the mixture and processed samples. The concentration is
expressed as the number of particles per microliter. (C) TEM image of iso-
lated exosome samples.
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volume of each outlet is 1.5× the input sample volume, reflecting
the PBS dilution effect during the course of separation, we corrected
the particle concentrations measured from NTA by dividing by
this dilution factor (1.5). We calculated that the original mixture
contained 1.03 × 108 particles per microliter that were smaller
than 140 nm and 3.34 × 108 particles per microliter that were
larger than 140 nm. The concentration of particles collected from
the exosome outlet was 8.42 × 107 per microliter (<140 nm) and
1.4 × 106 per microliter (>140 nm). At the microvesicle outlet, the
particle concentration was 1.8 × 107 per microliter (<140 nm) and
3.35 × 108 per microliter (>140 nm). The total numbers of vesicles
before and after separation were 4.37 × 108 per microliter and
4.386 × 108 per microliter, respectively, and the percentages of
small (<140 nm) particles were comparable before (23.6%) and
after (23.3%) separation. These values suggest that the acousto-
fluidics-based separation technique had a high sample yield with
minimal loss during the separation process. We defined the re-
covery rate as the fraction of particles recovered below 140 nm
among the particles of that size in the inlet solution. Similarly, we
define the purity of particle isolation as the fraction of isolated
particles below 140 nm among the collected particles of all sizes.
Overall, the present exosome-isolation device showed a recovery
rate and purity of 82.4% and 98.4%, respectively, for particles
smaller than 140 nm in diameter. Despite the demonstrated re-
covery rate and purity, it should be noted that the particles smaller
than 140 nm may contain nonexosomal particles and protein ag-
gregates, which could be considered contaminants for downstream
analysis of exosome.
Isolation of Exosomes from Undiluted Blood Using the Integrated
Device. Following testing and optimizing the individual mod-
ules, we integrated the cell-removal module and exosome-
isolation module into a single acoustofluidic chip. On this integrated
chip, the distance between the two modules was set sufficiently
apart to avoid interference between the acoustic fields of the two
modules, allowing the integrated device to operate as efficiently as
the optimized individual modules using the same parameters and
designs. We used undiluted human blood from healthy donors for
EV isolation (Fig. 5 and Fig. S4). The flow rates of each inlet were
set to 4 μL/min for the blood sample, 4 and 12 μL/min for sheath
flows in the cell-removal module, and 10 μL/min for sheath flow in
the exosome-isolation module. The driving frequency and voltage of
the input rf signal for the integrated device were the same as those
used for individual modules described above. When the acoustic
field was off, the blood stream was focused in the middle of channel
and directed into the device outlet F in Fig. 5 (Top Left). When the
rf signal was on for both modules, blood components were sepa-
rated into different outlets after passing through the cell-removal
module. The vast majority of blood cells and PLTs were deflected to
a cell waste outlet (outlet D in Fig. 5, Top Left) and the remaining
components continued to flow downstream to the exosome-
isolation module where the apoptotic bodies, microvesicles, and
the remaining part of cells are deflected to the vesicle waste outlet
(G in Fig. 5, Top Left), thereby isolating exosomes from whole-
blood samples in the device outlet (F in Fig. 5, Top Left), which we
subsequently refer to as the “exosome outlet.”
Upon collecting samples from the exosome and vesicle waste
outlets, we characterized the cell-removal efficiency. The origi-
nal blood sample, separated vesicle waste, and isolated exosome
sample were each collected into 1.5-mL centrifuge tubes and
spun at 3,000 rpm for 10 min. As shown in Fig. 6A, the volume of
cells in the whole-blood sample was nearly half of the total
volume, which is typical for human blood. In contrast, there were
few (<0.1%) blood cells remaining in the isolated exosome
sample and the vesicle waste (Fig. 6A). We further quantified the
number of blood cells in the exosome sample, using a hemocy-
tometer. The concentration of cells was 2.08 × 104 per milliliters
in the sample collected from the exosome outlet, while the RBC
count reference ranged from 4.7 to 6.1 × 1010 per milliliter,
yielding a cell-removal rate greater than 99.999%. We then
measured the size distribution of isolated exosome samples
through NTA. This was compared with NTA of plasma that was
separated from the whole-blood sample using standard centri-
fugation. The sample collected from the exosome outlet showed
a clear, narrow peak at around 100 nm, which corresponded to
exosomes, while the plasma control displayed a flat, disperse
curve covering a broad range from ∼50 nm to 1 μm (Fig. 6B). As
control, we isolated human plasma exosomes using OptiPrep
gradient ultracentrifugation, and compared the size distribution
of exosomes isolated by two different approaches. The peak of
exosomes using gradient ultracentrifugation was slightly larger
than that of exosomes using the acoustofluidic device (Fig. S5).
This difference could be explained by the effect of ultracentri-
fugation on exosomes, causing some aggregation of exosomes
and/or even fusion of small, “contaminating” particles (18, 35).
Collectively, the NTA results demonstrated that the acousto-
fluidic device differentiated subgroups of EVs based on size, and
thereby isolated exosomes from the mixture.
Having demonstrated the removal of blood components, in-
cluding RBCs, WBCs, PLTs, and microvesicles from undiluted
whole-blood samples, we sought to verify that the sample isolated
from blood is indeed composed of exosomes. We used Western
blot analysis to examine the expression of exosomal protein mar-
kers in the samples collected from all three outlets and a diluted
blood sample. We analyzed the expression of EV membrane tet-
raspanin CD63, membrane-binding protein TSG101, endoplas-
mic reticulum protein HSP90, and heat shock cognate protein
70 (HSC70). Among the four samples examined, the sample col-
lected from the exosome outlet showed a high expression of
HSP90, HSC70, CD63, and TSG101 (Fig. 6C), confirming the
presence of exosomes in the samples. These proteins were also
present in original blood samples, as expected. The other two
outlets, referred to as vesicle waste and cell waste, showed very low
levels of exosomal markers.
We further investigated whether exosomes isolated by our in-
tegrated acoustofluidic chip were contaminated by RBC’s RNA
transcripts. It has been demonstrated (36) that four mRNA genes
encoding Ferritin light chain (FTL), Glycophorin A (GYPA),
Fig. 5. Isolation of exosomes from whole blood using the integrated device
using acoustofluidics. In our experiments, inlet A is for whole blood; inlets B, C,
and E are for sheath flows. Outlet D is cell waste. Outlets F and G are for isolated
exosomes and vesicle waste, respectively. Images were taken under the micro-
scope at the corresponding areas of the device. Blood components were directed
to each corresponding outlet when the acoustic wavewas on.White stripe in the
four grayscale panels indicates the centerline location of the CCD image sensor.
(Scale bar: 500 μm.)
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Transferrin receptor (TFRC), and Solute carrier family 25 mem-
ber 37 (SLC25A37) are predominantly expressed in human RBCs.
We compared the relative levels of these transcripts in samples of
human blood input and isolated exosomes. We found that all four
transcripts expressed in RBCs were decreased by 75∼90% between
the input to the first module and the output from the second
module in our acoustofluidic device (Fig. 6D). Similarly, we ex-
amined relative levels of RBC-dominant miRNAs in whole blood
and isolated exosomes. miRNAs are known to be packaged in
exosomes and other extracellular vesicles, and RBCs strongly ex-
press four miRNAs including miR-144–3p, miR-451, miR-486–5p,
and miR-4732–3p (37–40). Consistent with the mRNA results (Fig.
6D), our miRNA results (Fig. 6E) indicated that isolated exosomes
barely, if any, expressed these four RBC miRNAs. We observed a
similar pattern of mRNA and miRNA expression using samples
derived from the gradient-based ultracentrifugation (Fig. S6). To-
gether, the mRNA and miRNA results suggest that the exosomes
isolated by our acoustofluidic devices have little contamination by
RBCs. Finally, we examined the morphology of isolated exosomes
using TEM. A large number of vesicles were, as marked by ar-
rows, of diameter ∼100 nm with cup-like concavity (Fig. 6F),
consistent with the established morphology of exosomes (41).
These results support the ability of our acoustofluidic platform to
isolate morphologically intact exosomes.
Discussion
We have demonstrated an acoustofluidic platform that is capable
of isolating exosomes directly from undiluted human blood. The
integrated device is based on acoustofluidics and contains two
separation modules, which provide the flexibility to handle
multiple subpopulations of a complex sample. By tuning the in-
put power of the rf signal and fluid flow rates, the cutoff size for
each of the two separation modules can be adjusted to ensure the
selection of specific subgroups. This feature enables the flexi-
bility to adjust for a range of particle sizes and applications.
Blood is one of the most complex biological fluids, with
components and properties that vary greatly among individuals
or within an individual at different time points. These factors
challenge existing separation techniques. Consider, for example,
the experimental hurdles arising from the blood lipid level. The
lipid particles have a negative acoustic contrast, in that they are
pushed to antinodes in the standing acoustic field. As such, lipid
particles concentrate at antinodes and tend to aggregate (36).
Aggregation of lipids disturbs laminar flow and the acoustic field
pattern, which in turn reduces separation efficiency. Therefore,
for blood samples with high lipid levels, the sheath/sample flow
ratio needs to be appropriately adjusted with an increased buffer
flow rate to suppress lipid aggregation. Another solution might
be the addition of a third acoustofluidic module designed to
remove lipids from undiluted blood.
With the current device configuration, we have successfully
separated and isolated bioparticles larger than 150 nm from exo-
somes. Notably, this isolated exosome sample may contain non-
exosomal particles and protein aggregates that have a size similar to
exosomes or smaller particles. To obtain exosomes with the highest
purity, we plan to integrate additional acoustofluidic-based sepa-
ration modules into the current device setup. As indicated in Table
S1, Fig. S7, and SI Simulation Assays for Isolating Nonexosomal
Particles and Soluble Proteins from Exosomes, these additional
acoustofluidic modules will allow us to further isolate exosomes
from (i) particles that have a similar size to exosomes (30–150 nm)
but different acoustic contract factors, and (ii) particles that are
smaller (i.e., <30 nm) than exosomes.
Our technology, predicated upon acoustofluidics, offers the
following distinct advantages over other available means to
separate exosomes from biological fluids:
i) Automation, high reproducibility, and biohazard contain-
ment: In conventional exosome-isolation assays, samples
need to be subjected to a multistep protocol using several
instruments. Throughout this process, a trained technician
must manually interact with the samples. In contrast, the
acoustofluidic approach can isolate exosomes (or other sub-
groups of EVs) directly from biological fluids (e.g., undi-
luted blood) with a single device in an automated manner.
Thus, it offers a simpler approach with enhanced biosafety
and a higher likelihood of consistent and reliable results.
Furthermore, after determining the optimal acoustic field
settings, routine operation of the acoustofluidic system re-
quires less training compared with conventional approaches.
ii) Exosome-separation speed: While differential centrifugation
approaches take hours to days for exosome isolation from
whole blood, the entire process to isolate exosomes from
100 μL undiluted human blood can be achieved within
∼25 min using acoustofluidics.
iii) Exosome yield and purity: We have demonstrated an exo-
some purity of ∼98% and a yield of ∼82% by using a mixture
Fig. 6. Characterization of exosome isolation from whole blood using the in-
tegrated acoustofluidic chip. (A) Removal of blood cells and PLTs. In the original
sample (undiluted whole blood), RBCs occupied approximately half of the vol-
ume. The isolated exosome sample and vesicle waste sample contain a minimal
amount of blood cells. (B) EVs in blood plasma showed a dispersed size distri-
bution that ranged between 30 nm and 1 μm. The size distribution of collected
exosome sample exhibited a major peak at <100 nm. (C) Western blot of exo-
some markers, showing a prominent expression in the isolated exosome and
blood samples, while the other samples (vesicle waste and cell waste) exhibited
low expression level of exosomal proteins. (D and E) The expression (expressed
as relative fold difference) of individual mRNAs (D) and miRNAs (E) in human
blood and isolated exosomes. The data represent three independent experi-
ments. *P < 0.05 (ANOVA) (F) TEM images of isolated exosomes. The exosomes
(red arrows) have a characteristic round shape and a cup-like structure.
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of purified exosomes and microvesicles derived from PHT
cells in our experiments.
iv) Continuous flow configuration: Many exosome-separation plat-
forms must be operated in batch mode. Acoustofluidics is ca-
pable of separating exosomes in continuous flow. Such devices
involving continuous flow can be conveniently integrated into
existing microfluidic-based exosome analysis device to enable an
all-in-one, on-chip exosome processing and analysis system.
v) Potential to isolate structurally intact and biologically active
exosomes: Many existing exosome-isolation technologies
have difficulties in isolating biologically active and structur-
ally intact exosomes; the isolation process often alters the
morphology, content, and functions of the exosomes (14, 18,
42). The present strategy offers a label-free, contact-free,
and potentially gentle method that has the potential to min-
imize disruption of the captured exosomes. The acoustic
power intensity and frequency we used in our experiments
are in a similar range to those in ultrasonic imaging, which
has been proven to be a safe technique. Using our device,
exosomes are exposed to a low-power-intensity acoustic field
for several seconds. This may compare favorably to differ-
ential centrifugation, which subjects exosomes to hours of
exposure to forces as high as 200,000 × g. This combination
of factors yields a higher likelihood of preserving the biolog-
ical, biophysical, and structural integrity of the isolated exo-
somes for further investigation.
Methods
Device Fabrication and Experimental Setup. The device is fabricated by stan-
dard soft-lithography and lift-off process. More details are in SI Device Fabri-
cation and SI Experimental Setup.
Isolation of Exosomes Using Gradient Ultracentrifugation. Exosomes were
isolated from whole-blood specimens using an OptiPrep gradient ultracen-
trifugation as previously described (16). The collection of placentas used for
cell isolation and culture was reviewed and approved by the Institutional
Review Board (IRB) at the University of Pittsburgh.
Characterization of Exosomes. The isolated exosomes are characterized by
NTA, Western blot, electron microscopy, and quantitative polymerase chain
reaction (qPCR). More details can be found in SI Characterization of Exosomes.
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